Try our Advanced Search for more refined results
Life Sciences - August, 2016
351 articles
- Medtronic Asks 9th Circ. To Flip $15M Loss In Device Trial
- Theranos Yanks New Zika Blood Test
- NY County Sues Drug Cos. Over Opioid Marketing
- Procter & Gamble Gets Bulk Of Fixodent MDL Cases Tossed
- 3 Takeaways From FDA's Off-Label Forum Plan
- Avalanche Aims To Ditch IPO Suit Over Eye Drug
- Convicted Ex-Acclarent Execs Shed Bail, Travel Requirements
- U. Of Minn. Says Gilead's $20B Hep C Drugs Flout Patent
- 2 Firms Grab Spotlight Amid Quiet August For IPOs
- Ohio Getting Closer To Authorizing Atty Medical Pot Work
- DC Circ. Ruling Dangerous For Hatch-Waxman: Takeda
- ITC Won't Appeal ClearCorrect Patent Ruling To High Court
- Lack Of Diligent Search Bars 2nd AIA Petition, PTAB Says
- HeartWare Says Investor Suit Over FDA Regs Is 'Opportunistic'
- FDA Adds Black Box Warnings About Mixing Opioids, Benzos
- Blood Sugar Monitor Maker Hit With Suit Over Car Crash
- Final Bellwether Trials Picked In Syngenta Tainted Seed MDL
- Abbott Calls Alere's $5.8B Merger Suit 'Publicity Stunt'
- 'Plain Language' Bars Pfizer's $8.3M Tax Suit, Gov't Says
- Reconciling The Practice With The Business Of Law
- Plavix Ruling Cements Calif. As Center For Mass Torts
- Celgene Battles $40B FCA Suit Over Off-Label Promos
- FDA Clears Sandoz Biosimilar Of Amgen's Enbrel
- AstraZeneca Will Pay $5.5M To SEC Over FCPA Claims
- Endo Vitamin Buyers Reach $15.5M Settlement Agreement
- FDA Warning Wire: Drugmaker VP Removed During Inspection
- Pfizer Wins Dismissal Of Zoloft Birth Defects Suit
- Merck Patent For Contraceptive NuvaRing Nixed As Obvious
- Actavis Wants Conspiracy Claim Nixed In Testosterone MDL
- Chicago Supplement Biz In FDA Hot Water Over Lead Levels
- In Search Of Objective Evidence Success At PTAB
- REBUTTAL: Establishing Standards And Norms In Mediation
- Calif. High Court Greenlights Non-Residents' Plavix Suits
- Trans Ova Says Halo Doesn't Reopen Sex-Selection IP Suit
- Otsuka Can't Duck Antitrust Claims Over Antipsychotic Drug
- NJ Pharma Co. Can't Revive Antitrust Suit Over Cough Syrup
- St. Jude Heart Devices Have Security Weaknesses, Suit Says
- Shire Seeks Toss Of Fortis Bid For $425M Drug Study Payout
- Pharma Co.'s Supply Chain Lies Caused Stock Drop, Suit Says
- GSK Can't Ax Out-Of-Staters From Ill. Paxil Suit, Court Says
- Icahn Boosts Herbalife Stake In Ongoing Battle With Ackman
- Convicted Ex-Acclarent Execs Don't Need Passports: DOJ
- Judge Rethinks Remand Of Mo. Residents' Benicar Claims
- Funding Litigation And Treatment: Leveling The Playing Field?
- Martin Shkreli Sells Remaining Stake In KaloBios
- Don't 'Discount' Gov't Opinion On Anti-Kickback Exception
- Brazilian Agency's Help In Lilly Coverage Row OK, Arch Says
- Mylan To Release $300 EpiPen Generic After Backlash
- DaVita Seeks End To Dialysis Suit
- Third-Party Payors Say GSK Skews Avandia Claims
- Health Hires: K&L Gates, Pharma Trade Org, Tucker Ellis
- Theranos To Appeal Sanctions Over Lab Lapses
- Deals Rumor Mill: Herbalife, Hurtigruten, China Vanke
- Alere Drags Abbott To Court In Bid To Force $5.8B Deal
- St. Jude Insists Cardiac Devices Are Safe From Cyberattacks
- FDA Wants Blood Donations Tested For Zika Nationally
- Globus Investor Suit Lacked 'Factual Allegations,' Judge Says
- Defining Attorney-Client Relationships In The Electronic Age
- Aveo Promises Reforms In Cancer Drug Derivative Settlement
- Taxation With Representation: Ropes, Cooley, Wachtell
- Exclusion Axes Anda's 'Pill Mill' Coverage, 11th Circ. Says
- FCA Attys Clash Over Escobar Test For Implicit Compliance
- Gilead, Emory Drop HIV Drug Generic Suit
- The Complexity Of Trademarks In The Marijuana Business
- $3.5B Auspex-Teva Merger Challenge Axed By Chancery
- St. Jude Cardiac Devices Carry Cyberattack Risk, Report Says
- FTC Wins Access To AndroGel Docs In AbbVie Antitrust Suit
- PTAB Won't Let Broad Seek CRISPR Docs From Fenwick
- Roxane Infringed Vanda's Antipsychotic Patent, Judge Rules
- E-Textiles: Regulating The Future Of Fashion
- Ill. AG Slams Insys Over Opioid Off-Label Marketing
- Real Estate Rumors: McKesson, Fla. Crystals, McSam Hotel
- 4 Reasons Law Firm Business Development Initiatives Fail
- Latham-Led Novan Files $60M IPO To Boost Acne Drug
- PE-Backed IBA Molecular Pays $690M For Nuclear Imaging Biz
- Mylan's Changes To EpiPen Prices A 'PR Fix,' Senator Says
- PTAB Scraps 2 Teva Copaxone Drug Patents After Review
- Calif. Theranos Actions Combined Into Single Suit
- Drugmaker MannKind Beats Shareholder Securities Suit
- DOJ Gets Kickback Case Revived Against Medical Supplier
- Clinton, AMA Join Backlash Against EpiPen Price Hikes
- Canada, Lilly Make Last Pleas In Patent Policy NAFTA Row
- Medicare Settlements In Tainted Steroids MDL Get Early OK
- Actavis Uses Nautilus To Ax Claims In Horizon Pennsaid Case
- Drugmaker Had Too Much Control To Duck $6M Tax Deficiency
- Express Scripts Must Face Pharmacies' Antitrust Claims
- Toronto Exchange Owner Funds New Tech Growth Group
- Zydus Can't Escape Wrongful Death Suit, Judge Says
- Cephalon, Sagent Ink Deal In Generic Cancer Drug Fight
- Dexcom Suit Says It's Not Poaching InSpark Glucose Patents
- Omnicare Can't Kick Whistleblower's $421M FCA Suit
- 3rd Circ. Backs Bigger Damages For Infringement Of Rare Pics
- Prolias Suit Against PDI Tossed For Not Getting New Counsel
- Lilly Fights Brazilian Agency Wading Into Arch Squabble
- FTC Alums: Retail Mergers Reflect New Approaches At FTC
- Ropes & Gray Leads Pfizer In Deal For AstraZeneca Unit
- Pay-For-Delay & Stock Prices: Smoking Gun Or Damp Squib?
- Rainmaker Q&A: Duane Morris' Matthew Taylor
- Turing Exec Says Punishment Followed Sex Assault Inquiry
- Boston Judge Leans Toward Remanding La. GranuFlo Case
- Judge Nixes Eli Lilly's Axiron Patents In Win For Generics
- 'Permissive' USPTO Patent Policies Raise Drug Prices: Study
- FDA Warning Wire: Aloe Vera Farm Gets Agency Burn
- Genentech Seeks Quick Win In Cancer Drug Dosage Case
- Kasowitz Benson Says Chem Cos. Hid Risks, Owe Billions
- 9th Circ. Affirms Arbitration For 23andMe In Marketing Case
- R&D Impact May Be Key In Scrutiny Of Pfizer Oncology Deal
- Cinven Shells Out $1.4B For PE-Backed BioClinica
- Proposed Class Action Over 'Organic' Baby Food Tossed
- Eli Lilly Urges 9th Circ. Not To Revive Cymbalta Suit
- Transport Cos. Shake Claims In $9M Drug Theft Dispute
- Warner Says Aggrenox Court Erred In Pay-For-Delay Case
- DLA Piper Attys Say Insurer's Sanctions Bid Distorts Record
- From BigLaw To Your Own Firm: 4 Tips For Legal Startups
- FTC Alums: 5 Institutional Challenges For The FTC
- Rainmaker Q&A: Sills Cummis' Beth Rose
- NJ Reglan Ruling Widens Generic Label Preemption Split
- Judge Explains Rulings In Acclarent Criminal Cases
- Inside Sanofi's Failed $9.3B Pursuit Of Medivation
- Investor Agrees To Drop FedEx Drug Shipping Derivative Suit
- Nebraska Couple's Reglan Claims Time-Barred, Judge Says
- Deals Rumor Mill: Empresas, Renesas Electronics, Cinven
- Senator Asks FTC To Investigate Mylan's EpiPen Price Soar
- Colo. Dispensary Moves For Refund In Marijuana Tax Row
- Biotech Asks Full Circ. To Resolve Patent Review Conflict
- Nestle And Galderma Hit Perrigo With IP Suit Over Generic
- 3 Companies Reboot IPO Pipeline With $255M In New Filings
- Medline Hit With NJ Suit Over Burning Dangers Of Cold Pack
- 4 Communications Fundamentals For High-Stakes Litigation
- Revolutionizing UK Product Recall Action?
- FTC Alums: SMARTER Changes To FTC Merger Reviews
- Reglan Suits Not Preempted By Federal Law, NJ Justices Say
- Pfizer Wins Over Medivation With $14B Buyout
- Respecting The Rules For Searching Jurors' Social Media
- Ethicon's Noncompete Claim Can't Beat Calif. Law, Suit Says
- Lipitor Buyers Say Claims Can't Be Axed Before Discovery
- Texas Jury Clears Spinal Device Co. In Patent Suit
- Wipeout Of Mirena MDL To Be Challenged At 2nd Circ.
- Sheppard Mullin Adds Crowell & Moring Gov't Contracts Pro
- SEC Blasts Stay Bid Pending High Court Action In Salman
- Surgery Center Objects To Remand Bid In Meningitis MDL
- Sequenom Investor Wants Tender Offer Halt In LabCorp Buy
- FDA Barred From Shutting Down Tissue Therapy Co.
- Insurance Co. Fights Sanctioned DLA Atty Testimony Request
- Abilify Whistleblowers Want 6th Circ. To Revive FCA Suit
- FDA Needs Plan To Regulate Clinical Software, Group Says
- Class Attys Seek $1.5M Fee On $5.4M Shareholder Gain
- 'Schwarzenegger' Supplement Maker Defends Protein Claims
- J&J Fights $500K Risperdal Verdict At Pa. Appeals Court
- Deals Rumor Mill: Wako Pure Chemical, Vale, Starwood
- Greenland Venture Buys 42-Acre South San Francisco Site
- FTC Alums: Focusing On The FTC With 2020 Vision
- Meningitis Victim Statements Barred At Investor's Sentencing
- Risk Management Tips For Attys Serving As Local Counsel
- Ex-Novartis Worker's Suit Tossed For Deceiving NJ Court
- Steamfitters Funds Chosen To Lead Endo Class Action
- Pentair To Net $3.15B In Sale Of Valves Business To Emerson
- Pfizer Ducks Lipitor Fraud Claims Suit Again In 2nd Circ.
- MRI Patent Suit Tests Bounds Of Williamson
- 9th Circ. Remands Diabetes Suit Instead Of Dismissing
- Ex-Acclarent Execs Want Travel Restrictions Lifted
- 'Nothing Nefarious' About Alleged Kickbacks, Supplier Says
- T. Rowe, Alleghany Go After Valeant For Stock Drop
- Deals Rumor Mill: Illumina, Rentex, Clover Technologies
- Ohio High Court To Review Attys' Services To Marijuana Cos.
- Washington Must Pay For State Employees' Hep C Treatment
- Bayer, Global Product VP Hit With Gender Bias Suit In NJ
- Ex-Insys Staffers Plead Not Guilty In Opioid Kickback Suit
- DTSA — New Strategy For 'Bring Your Own Cloud' Issues
- Patent Term Extension Not A 1-Trick Pony For Animal Drugs
- Dorsey Backs Away From Controversial Shkreli Invite
- Sanctioned DLA Piper Atty Raises Doubts On Key Testimony
- Eli Lilly Subsidiary Gets $3.9M In Fees Under Octane Ruling
- Costco, Apotex Generic Lipitor Labeling Suit Hits 9th Circ.
- Shkreli Seeks Escape From KaloBios Securities Litigation
- Dusek Doesn't Bar Merck Investors' Claims, 3rd Circ. Hears
- IKOR, Execs Denied New Trial, But Get Damages Slashed
- Hyland's Beats Remaining Claims After False Ad Suit Verdict
- Janssen Loses Fight To Keep Remicade Patent In Force
- 5th Circ. Upholds Dismissal Of Faulty Spinal Implant Suit
- Beware The 'Standard' Mediation Confidentiality Agreement
- Deals Rumor Mill: Wako Pure Chemical, MSG, Brookfield
- Pfizer Says $8.3M Tax Interest Row Belongs In NY Court
- Equistone Partners Buys Into German Peroxide Chemicals Co.
- CVC To Exit Chemical Co Univar In $398M Stake Sale
- 9th Circ. Affirms Toss Of NuBone Safety Claims
- Janssen Faces Mixed Prospects In Immuno Drug IP Suit
- Sequenom Investors Sue To Block LabCorp Takeover Bid
- Suboxone Maker Says Docs Are Withheld In Product-Hop MDL
- Invalidity Of Bovine Sperm Patent Is Bull, Court Told
- Ex-Pfizer Doc Asks Court To Rethink His Fraud Claims Suit
- PeriCor Asks Judge To Nix 'Biased' Merck Arbitration Award
- FDA Warning Wire: A Midsummer Enforcement Bonanza
- Rutgers Wants BioArray IP Licensing Suit Back In State Court
- UCB's Anti-Convulsant Patent Is Valid, Delaware Judge Rules
- Ky. AG Hits J&J With Pelvic Mesh Deceptive Marketing Suit
- Seeger Weiss Immune From $6.9M Vioxx Row, 5th Circ. Told
- Pfizer Unit's Patent For Antibiotic Drug OK'd By Fed. Circ.
- Arch Seeks Brazilian Insurance Regulator's Aid In Lilly Row
- Swiss Biotech Lonza Pays Up To $300M For Ingredients Maker
- 5 Mistakes To Avoid When Building Law Libraries
- Bovine Sperm Monopoly Still Wins $2M Patent Verdict
- PTAB Again Upholds Verinata Patent After Fed. Circ. Remand
- Cipro Buyers Want OK For $100M Pay-For-Delay Settlement
- Express Scripts Investor Demands Look At Books, Records
- FTC Wins False Ad Case Against Gray Hair Supplement Maker
- FDA's Abilify Logic Invites 'Gamesmanship,' Otsuka Says
- BALCA Says Wage Range In Posting Doesn't Nix Labor Cert.
- New Trial Unlikely After $70M Neovasc Verdict, Judge Says
- Fed. Circ. Finds Pill-Dispensing Patent Valid Again
- Bristol-Meyers, Pfizer Hid Eliquis Risks, $10M Suit Alleges
- Rainmaker Q&A: Kilpatrick Townsend's Tina Williams McKeon
- DOJ, Defense Attys Brawl Over Escobar's FCA Impact
- Deciding Where To File Patents Internationally In 2016
- Law Students Should Explore BigLaw Pro Bono Options
- Does Your D&O Policy Cover Informal SEC Investigations?
- Drugmakers Hit With Suit Over Nerve-Damaging Antibiotic
- Medtronic Seeks To Nix State-Law Claims In FCA Suit
- Texas Court Revives UBS Shareholder Defamation Suit
- Gilead Says Indian Co. Is Infringing HIV Drug Patents
- Taxation With Representation: Fenwick, Sullivan, Gibson Dunn
- Judge Tacks $6M In Delay Damages To $70M Risperdal Award
- Health Hires: KDB, Rubin Add Scientists As IP Partners
- Ceragenix Wins Dismissal Of Ex-Exec's SOX Complaint
- Calif. Pair Faces Insider Trading Charges In Biotech Scheme
- Lab Affiliates Want Meningitis Victims Silent At Sentencing
- Abbott Must Hand Over Old Depositions In Whistleblower Suit
- Gilead Entitled To Fees Over Merck Misconduct, Judge Says
- Bard Again Slams Gore's 'Baseless' Sanctions Bid In IP Suit
- FTC Wins AndroGel Info From AbbVie In Antitrust Suit
- Bausch & Lomb Settles Eye Vitamin Patent Suit During Trial
- Hagens Berman Clients May Be Allowed To Drop GSK Claims
- Endo, Impax Face Leaner Opana Pay-For-Delay MDL
- Ancestry.com Wants 6th Circ. To Shut Down 'AncestryByDNA'
- Acella Escapes Skin Disorder Drugs Trade Secrets Suit
- Brother's Firm May Cause Judge DQ In Supplement MDL
- PE-Backed Medpace Soars Among 2 IPOs Totaling $251M
- Pre-AIA And Post-AIA Issues Presented By The On-Sale Bar
- Eli Lilly, Canada Spar Over $383M NAFTA Arbitration Claim
- Calif. Judge Rejects False-Ad Class Action Settlement
- Drug Co. Wins Deferral Treatment Of $2.8M Income Gain
- Ex-Hunton Attorney & Pal Charged With Insider Trading
- Novo Nordisk's $305M Campus Sale Sets NJ Record For 2016
- Daiichi, Forest Ask Judge To Rethink Benicar Mo. Remand
- 7th Circ. Tightens Standards For Disclosure-Only Deals
- Deals Rumor Mill: Jeld-Wen, Samsung, Entertainment One
- PE Owners Exit Zimmer Biomet In $965M Secondary Sale
- 3rd Circ. Pauses Trading Case Over SEC, Trader Objections
- Enviros Scold FDA Over Genetically Modified Mosquito Plan
- Fed. Circ. Upholds PTAB's Suboxone Patent Invalidation
- Pfizer Can Argue It Invented Cattle Treatment Before Bayer
- Sagent Hit With Investor Suit Over Proposed Merger
- Some Indirect Claims Stay In Aggrenox Pay-For-Delay Row
- 2 Cooley-Led Biotechs Price $920M In Follow-On Stock Sales
- Return Of Exec Accountability Creates Compliance Challenges
- Fed. Circ. Says PTAB Spinal Patent Ruling Needs Elaboration
- Novartis Korea Execs Indicted, Accused Of Bribing Docs
- FDA Warning Wire: Pfizer Hospira Plant Troubles
- Chicago Says Recent Decision Backs Opioid Marketing Suit
- Investor Claims Biopharma Withheld Patient Testing Info
- SynCardia Unsecured Creditors Dispute Secured Tort Liens
- Allergan Scores $58M Tax Break To Remain In NJ
- DOJ Says Judge Misread Kickback Exception In FCA Case
- 1st Circ. Told No Fraud Was Public Before Covidien FCA Suit
- NY Pharmacist Convicted In Black Market HIV Meds Scheme
- Writing Arbitration Clauses To Get The Arbitration You Want
- Fla. Drug Co. Recalls Liquid Products Over Bacteria
- FDA's Pursuit Of A National Medical Device Evaluation System
- Abbott Still Worried About Alere Pact Even After SEC Filing
- Medical Device Maker CVRx Nabs $113M In Financing
- Medical Scrub, Garment Maker Hit With False Advertising Suit
- EQT Buys Health Care Analytics Co. In $2.35B Deal
- Synthes Reaches $5M Proposed Settlement In Expenses Suit
- AstraZeneca Says Mylan Can't Sell Cancer Generic Till 2019
- Cephalon To Pay $125M To Settle Provigil Antitrust Litigation
- DC Circ. Won't Rehear Czech $325M Arbitration Fight
- Medical Tech-Focused BioVentures In Midst Of Raising $100M
- SEC, Insider Tell 3rd Circ. Not To Wait For Salman Ruling
- CR Bard Blasts Rival's 'Baseless' Sanctions Bid In IP Suit
- Express Scripts Says Claims In $15B Pricing Dispute Hold Up
- Biogen Escapes Negligence Suit Over MS Drug Labeling
- Bristol-Myers Directors Sued in NY Over FCPA Inaction
- NuScience Wants Brothers Jailed For Threats During IP Fight
- 9th Circ. Questions Validity Of NuBone Safety Claims
- AbbVie Hit With Hedge Fund's Suit Over Failed Shire Deal
- GSK May See Payor Exit Diabetes Drug Suit On Own Accord
- Genetically Modified Mosquitoes' Trial Run Inches Closer
- Taxation With Representation: Latham, Fenwick, Kirkland
- Hospira Can't Beat Amgen's Biosimilar Notice Suit
- Zoetis Says AX Pharmaceutical Imports Infringing Dog Drug
- Amgen's Humira Biosimilar Infringes 61 Patents, AbbVie Says
- Judge Narrows Case Against Doc In Fatal Meningitis Outbreak
- Fed. Circ. Hands Win to Supplement Co. In Patent Suit
- 4 Firms Poised To Steer IPOs Totaling $270M
- Deals Rumor Mill: Apollo Global, Nissan, Valeant
- Ex-Va. First Lady's Appeal Paused After High Court Reversal
- A Review Of Key Criminal Cases Against Execs In Q2
- Meningitis Victims Ask For Preliminary OK Of CMS Settlement
- U. Of Wash. Wins Trial Over Woman's Surgery Death
- Why High Court Hasn't Reviewed Structural Obviousness Test
- 3 Ways To Avoid Antitrust Issues When Launching A Redesign
- 9 Tips For Becoming A Legal Pundit In The Media
- Gilead's $15M Fee Bid On Table After Merck Witness' Lies
- Calif. State Judge Preserves Essure Injury Claims
- Liberty Off Hook For MusclePharm's $3M Indemnity Claim
- Doctor In Charge Of Drug Trial Accused Of Insider Trading
- US Chamber Challenges Anti-Tax Inversion Rule
- PTAB Knocks Out 2 Eli Lilly Cialis Patents In AIA Reviews
- NY AG Ends Noncompetes At Medical Information Company
- Law Firm Employees Can Better Defend Against Cyberthreats
- Surgery Center Calls 'Facts' In Meningitis Suit Irrelevant
- Whistleblowers Call Med Supplier's Discounts Kickbacks
- AIG Unit Asks 9th Circ. To Nix $3.7M Ad-Suit Coverage Ruling
- GSK, Actavis Dodge RICO Claims In Testosterone Case
- Judge Tosses Investors' Suit Over $140M ConforMIS IPO
- Former DOJ Officials Warn Against Bayer-Monsanto Merger
- PTAB Nixes Carnegie Mellon's Joint Placement Patent Claims
- Fed. Circ. Urged To Reverse PTAB Ruling On Opiate Treatment
- FDA's Biosimilar Labeling Vision Stirs Up Discord
- INC Research Investors Prime $210M Secondary Offering
- NY Firm Tells 11th Circ. Ex-Client Admitted To Owing Fees
- Allergy Test Maker Says Physician Antitrust Claims Off Base
- Shire, DOJ Reach $350M Deal In Dermagraft FCA Investigation
- J&J Wants Talc Trial Moved Due To Plaintiffs' Atty Ads
- FDA Warning Wire: Listeria Outbreak, 'Cosmeceuticals'
- AARP Urges 3rd Circ. To Revive Eye Drop Suit
- Deals Rumor Mill: Biogen, Aetna, Enbridge
- Pillsbury Nabs Corporate Transaction Pro From DLA Piper
- SynCardia Gets Nod For DIP Loan, $19M Auction Plan
- No Need For Hearing Vetting Suicide Expert, Atty's Widow Says
- Ex-Acclarent Execs Want Misdemeanor Convictions Tossed
- Pfizer To Pay $486M To Settle Celebrex, Bextra Securities MDL
- Fed. Circ. Clarifies The Test For Patentable Subject Matter
- FDA Streamlines Reviews Of Next Generation Sequencing Tests
- State-Of-The-Art Defense And The Internet Of Things
- SynCardia May Pivot To Private Bankruptcy Sale
- J&J Unit, Surgeon Owe Millions For Woman's Death, Jury Told
- Mirena MDL Shows How A Lack Of Experts Can Doom A Case
- FTC Urges Quick Ruling On Lidoderm, Opana Severance Bid
- Advent Takes 50% Stake In Biopharma Services Co. InVentiv
- J&J Unit Reaches Settlement In Tylenol Death Suit
- Deals Rumor Mill: Hewlett Packard, Recordati, Old Mutual
- Greenspoon Marder Picks Up Fla. Health Boutique
- Novartis Leukemia Drug Buyers Blast 'Sham' Patent Suit
- UT Immunology Prof Claims School Forced Her Out Over Age
- Exploring The FDA's Clarification On Biosimilar Labeling
- FTC, Hair Supplement Co. Duel For Quick Wins In False Ad Suit
- CytRx Hit With 2nd Investor Suit Over Cancer Drug Trial
- NJ Arbitration Agreements: It's All In The Language
- GSK, Alphabet Join Forces With $712M Bioelectronics Venture
- BigLaw's (Crowded) Passage To India?